...
首页> 外文期刊>Metabolism: Clinical and Experimental >Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study.
【24h】

Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study.

机译:在高胆固醇血症受试者中,联合依泽替米贝和盐酸考来维仑的脂蛋白作用与单独的依泽替米贝相比:一项初步研究。

获取原文
获取原文并翻译 | 示例

摘要

Two drug classes act in the intestine to lower cholesterol. Ezetimibe inhibits cholesterol absorption, whereas bile acid-binding resins enhance cholesterol excretion via enhanced conversion to bile acids. Combining these 2 classes may be beneficial, but cholestyramine binds ezetimibe, and the combined effect of colesevelam hydrochloride and ezetimibe was little studied. The aim of the study was to determine if adding colesevelam HCl to ezetimibe provides additional lowering of low-density lipoprotein- and apolipoprotein B-containing lipoproteins or alters ezetimibe levels. Twenty subjects with low-density lipoprotein cholesterol (LDL-C) levels of 130 mg/dL or higher were enrolled and taught a National Cholesterol Education Program Step I diet. At a second baseline visit, lipoproteins were measured and subjects were randomly allocated to (1) ezetimibe 10 mg daily with placebo colesevelam HCl twice daily (E) or (2) ezetimibe 10 mg daily with 1.875 g colesevelam HCl twice daily (E + C). Lipoproteins were measured 6 and 12 weeks after initiating treatment. Baseline characteristics (mean +/- SD) were statistically indistinguishable in E vs E + C: LDL-C (mg/dL), 167 +/- 26 and 158 +/- 27; triglyceride, 134 +/- 75 and 140 +/- 67; and BMI, 29.4 +/- 4.9 and 27.8 +/- 6.6 kg/m(2), respectively. Percent changes after 12 weeks in E vs E + C were as follows: LDL-C, -24 +/- 12 vs -30 +/- 11 (P = .102); triglyceride, -19 +/- 34 vs 36 +/- 85 (P = .054; at 6 weeks, P = .009); total cholesterol, -19 +/- 9 vs -15 +/- 8 (P = .50); non-high-density lipoprotein cholesterol, -25 +/- 10 vs -21 +/- 11 (P = .70); apolipoprotein B, -31 +/- 14 vs -22 +/- 14 (P = .41). Plasma ezetimibe levels at 12 weeks were 21% lower in E + C vs E, a nonsignificant difference (P = .54). In conclusion, in the short term, colesevelam HCl may not consistently add cholesterol-lowering benefit to ezetimibe. This observation requires confirmation.
机译:肠道中有两种药物可降低胆固醇。依泽替米贝抑制胆固醇的吸收,而结合胆汁酸的树脂通过增强转化为胆汁酸的方式来增强胆固醇的排泄。合并这两种药物可能是有益的,但是胆甾醇胺与依泽替米贝结合,而盐酸考来维仑和依泽替米贝的联合作用很少研究。该研究的目的是确定向依泽替米贝中添加盐酸西西美仑是否能进一步降低低密度脂蛋白和载脂蛋白B脂蛋白的含量或改变依泽替米贝的水平。低密度脂蛋白胆固醇(LDL-C)水平为130 mg / dL或更高的20名受试者入选,并接受了美国胆固醇教育计划第一步饮食。在第二次基线访视时,测量脂蛋白,将受试者随机分配至(1)每日两次10 mg的依泽替米贝,每天两次安慰剂盐酸盐酸西泽韦仑(E)或(2)每日两次ezetimibe 10毫克,与盐酸两次口服依西米芬1.875 g每天两次(E + C )。在开始治疗后6周和12周测量脂蛋白。 E与E + C的基线特征(平均值+/- SD)在统计学上没有区别:LDL-C(mg / dL),167 +/- 26和158 +/- 27;甘油三酸酯,134 +/- 75和140 +/- 67;和BMI分别为29.4 +/- 4.9和27.8 +/- 6.6 kg / m(2)。 E vs E + C 12周后的变化百分比如下:LDL-C,-24 +/- 12 vs -30 +/- 11(P = .102);甘油三酸酯,-19 +/- 34 vs 36 +/- 85(P = .054; 6周时,P = .009);总胆固醇,-19 +/- 9 vs -15 +/- 8(P = 0.50);非高密度脂蛋白胆固醇,-25 +/- 10 vs -21 +/- 11(P = .70);载脂蛋白B,-31 +/- 14 vs -22 +/- 14(P = 0.41)。与E相比,E + C的12周血浆依泽替米贝水平降低了21%,差异无统计学意义(P = .54)。总之,从短期来看,盐酸西洛韦仑可能不会一直为依泽替米贝增加降低胆固醇的益处。此观察需要确认。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号